NOS2 and type 2 diabetes mellitus: This is the first evidence of the ability of melatonin to counteract iNOS-mediated inflammatory and stress effects in HEMA- and CQ-treated hDPCs, which could be a mechanism of significance for the modulation of presently observed immediate postoperative sensitivity after composite restoration in type 2 diabetic patients (Figure 7).